Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
I-Mab Biopharma (Hangzhou) Co. Ltd. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 matter is being reviewed by 1 distinct examiner in 1 distinct art unit. Such a focused portfolio indicates that the company's current prosecution efforts are concentrated on a specific set of claims or technology. This simplicity in the portfolio structure means that resources can be dedicated to addressing the specific requirements of this 1 pending action. Practitioners can observe that the company's current interactions with the patent office are limited to these specific parameters.
NICKOL, GARY B is the busiest examiner for this company, with 1 pending office action under their supervision. As the busiest examiner pending count is 1, this individual is responsible for the company's active office action load. The prosecution path for the company is currently defined by this 1 interaction within the designated art unit. Practitioners should focus on the specific examination history of the 1 distinct examiner to navigate the 1 pending office action successfully. This focus allows for an analysis of the examiner's past actions and the art unit's requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 47.1% | +31.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270139 | FORMULATION CONTAINING SOLUBLE GP130 DIMER AND METHOD FOR USING SAME | NICKOL, GARY B | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270139 | FORMULATION CONTAINING SOLUBLE GP130 DIMER AND METHOD FOR USING SAME | NICKOL, GARY B | 1643 | §103 | Non-Final OA | 10d overdue | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial